1.	Phase III Randomized Study of Intraperitoneal AD 32 Versus Oral Altretamine in Patients with Refractory or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Who Have Failed Platinum and Paclitaxel Chemotherapy (Summary Last Modified 06/2000) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ANTHRA-A9503
2.	Phase III Randomized Study of AD 32 Following Transurethral Resection in Patients with Newly Diagnosed or Recurrent Superficial Transitional Cell Carcinoma of the Bladder (Summary Last Modified 08/2000) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ANTHRA-A9601, NCT00003725
3.	Phase II Study of Intravesical AD 32 (a Doxorubicin Analogue) for in Situ Transitional Cell Carcinoma of the Bladder Refractory to BCG (Summary Last Modified 09/98) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ANTHRA-A9301/02, NCI-V95-0695
4.	Phase II Study of Intravesical AD 32 (a Doxorubicin Analogue) for in Situ Transitional Cell Carcinoma of the Bladder with or without Prior BCG (Summary Last Modified 09/98) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ANTHRA-A9303, NCI-V95-0696
5.	Phase II Study of Intravesical AD 32 in Patients with Recurrent or Refractory Papillary Transitional Cell Carcinoma and/or Carcinoma In Situ of the Bladder Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: E-3897, NCT00003129, E3897
6.	Phase II Randomized Study of Peri-Operative Intravesical AD 32 Alone or Supplemented with BCG in Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ANTHRA-A9701/ID97-038, MDA-ID-97038, NCT00003759
7.	Phase II Evaluation of Chemotherapy with AD-32 for Patients with Measurable Metastatic Malignant Disease Phase: Phase II Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: DFCI-78061
8.	Retrospective Chart Review of Valstar Phase: No phase specified Type: Natural history/Epidemiology Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EN3329-401, NCT01304173